Neil Everett Martin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 79 | 2024 | 11345 | 3.130 |
Why?
|
Androgen Antagonists | 21 | 2024 | 1442 | 1.300 |
Why?
|
Prostatectomy | 24 | 2024 | 1956 | 1.260 |
Why?
|
Testicular Neoplasms | 10 | 2024 | 801 | 1.160 |
Why?
|
Prostate-Specific Antigen | 19 | 2023 | 2529 | 1.110 |
Why?
|
Brachytherapy | 17 | 2021 | 1238 | 1.000 |
Why?
|
Radiosurgery | 6 | 2023 | 1343 | 0.940 |
Why?
|
Prostate | 12 | 2024 | 1793 | 0.820 |
Why?
|
Kallikreins | 3 | 2018 | 231 | 0.700 |
Why?
|
Health Status Indicators | 2 | 2015 | 968 | 0.670 |
Why?
|
Radiation Oncology | 4 | 2019 | 563 | 0.660 |
Why?
|
Hearing Loss | 6 | 2024 | 780 | 0.660 |
Why?
|
Tinnitus | 4 | 2023 | 194 | 0.550 |
Why?
|
Tosyl Compounds | 2 | 2014 | 112 | 0.510 |
Why?
|
Patient-Centered Care | 3 | 2016 | 1416 | 0.500 |
Why?
|
Quality Indicators, Health Care | 2 | 2015 | 1824 | 0.480 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1190 | 0.480 |
Why?
|
Antineoplastic Agents, Hormonal | 5 | 2017 | 1529 | 0.460 |
Why?
|
SEER Program | 18 | 2019 | 1530 | 0.460 |
Why?
|
Critical Pathways | 1 | 2017 | 475 | 0.460 |
Why?
|
RNA, Neoplasm | 2 | 2015 | 749 | 0.440 |
Why?
|
Medical Oncology | 2 | 2015 | 2313 | 0.430 |
Why?
|
Anilides | 2 | 2014 | 409 | 0.420 |
Why?
|
Flutamide | 1 | 2012 | 95 | 0.400 |
Why?
|
Health Status | 2 | 2015 | 4081 | 0.390 |
Why?
|
Radiotherapy | 5 | 2019 | 1504 | 0.370 |
Why?
|
Nitriles | 2 | 2014 | 956 | 0.360 |
Why?
|
Quality of Health Care | 3 | 2020 | 4360 | 0.330 |
Why?
|
Language | 1 | 2019 | 1533 | 0.330 |
Why?
|
Complementary Therapies | 1 | 2013 | 486 | 0.330 |
Why?
|
Male | 95 | 2024 | 359744 | 0.320 |
Why?
|
Cisplatin | 6 | 2024 | 1644 | 0.320 |
Why?
|
Adenocarcinoma | 6 | 2019 | 6315 | 0.310 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 3 | 2024 | 494 | 0.290 |
Why?
|
Neuralgia | 2 | 2024 | 600 | 0.290 |
Why?
|
Survivors | 3 | 2024 | 2375 | 0.290 |
Why?
|
Bone Neoplasms | 3 | 2017 | 2532 | 0.280 |
Why?
|
Health Personnel | 1 | 2020 | 3310 | 0.270 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2013 | 1375 | 0.260 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2864 | 0.260 |
Why?
|
Humans | 107 | 2024 | 760621 | 0.250 |
Why?
|
Neoplasm Staging | 17 | 2019 | 11152 | 0.250 |
Why?
|
Aged | 67 | 2024 | 169152 | 0.250 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2315 | 0.240 |
Why?
|
Cancer Care Facilities | 3 | 2017 | 424 | 0.240 |
Why?
|
Testosterone | 2 | 2014 | 2470 | 0.240 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 86 | 0.230 |
Why?
|
Neoplasms, Second Primary | 4 | 2021 | 1056 | 0.220 |
Why?
|
Healthcare Disparities | 6 | 2016 | 3388 | 0.220 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.200 |
Why?
|
Middle Aged | 58 | 2024 | 220352 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.200 |
Why?
|
Neoplasms | 7 | 2022 | 22072 | 0.200 |
Why?
|
Travel | 2 | 2018 | 785 | 0.200 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5325 | 0.200 |
Why?
|
Tumor Burden | 3 | 2024 | 1895 | 0.190 |
Why?
|
Health Behavior | 1 | 2013 | 2622 | 0.190 |
Why?
|
Exercise | 2 | 2015 | 5787 | 0.190 |
Why?
|
Logistic Models | 12 | 2024 | 13314 | 0.190 |
Why?
|
Particle Accelerators | 1 | 2021 | 174 | 0.180 |
Why?
|
Salvage Therapy | 3 | 2017 | 1268 | 0.180 |
Why?
|
Proportional Hazards Models | 16 | 2020 | 12531 | 0.180 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3202 | 0.180 |
Why?
|
Marital Status | 4 | 2015 | 433 | 0.180 |
Why?
|
Watchful Waiting | 3 | 2019 | 510 | 0.170 |
Why?
|
Pandemics | 1 | 2020 | 8624 | 0.170 |
Why?
|
Palliative Care | 2 | 2017 | 3607 | 0.170 |
Why?
|
Databases, Factual | 10 | 2019 | 8035 | 0.160 |
Why?
|
PTEN Phosphohydrolase | 2 | 2015 | 1115 | 0.160 |
Why?
|
Antineoplastic Agents | 6 | 2024 | 13630 | 0.160 |
Why?
|
Quality of Life | 4 | 2024 | 13308 | 0.160 |
Why?
|
Anti-Anxiety Agents | 1 | 2021 | 397 | 0.150 |
Why?
|
Imidazoles | 1 | 2004 | 1180 | 0.150 |
Why?
|
Academic Medical Centers | 3 | 2017 | 2754 | 0.150 |
Why?
|
Divorce | 1 | 2018 | 76 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 299 | 0.150 |
Why?
|
Anxiety | 2 | 2024 | 4538 | 0.150 |
Why?
|
Risk Assessment | 12 | 2020 | 24123 | 0.150 |
Why?
|
Speech Perception | 1 | 2022 | 505 | 0.150 |
Why?
|
Fatigue | 1 | 2024 | 1544 | 0.140 |
Why?
|
Diet | 1 | 2015 | 8010 | 0.140 |
Why?
|
Organizational Case Studies | 1 | 2017 | 301 | 0.140 |
Why?
|
Risk Factors | 22 | 2024 | 74359 | 0.140 |
Why?
|
Radiation Injuries | 2 | 2014 | 1183 | 0.130 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2023 | 3765 | 0.130 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2018 | 1791 | 0.130 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2022 | 708 | 0.130 |
Why?
|
Pancreatic Neoplasms | 2 | 2023 | 5351 | 0.130 |
Why?
|
Treatment Outcome | 19 | 2017 | 65017 | 0.130 |
Why?
|
Aged, 80 and over | 22 | 2019 | 58995 | 0.130 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8552 | 0.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2021 | 801 | 0.120 |
Why?
|
Disease-Free Survival | 5 | 2017 | 6828 | 0.120 |
Why?
|
Immunohistochemistry | 5 | 2015 | 11071 | 0.120 |
Why?
|
United States | 26 | 2019 | 72461 | 0.120 |
Why?
|
Smad4 Protein | 1 | 2015 | 191 | 0.120 |
Why?
|
Vasectomy | 1 | 2014 | 51 | 0.120 |
Why?
|
Prognosis | 12 | 2024 | 29658 | 0.120 |
Why?
|
Time Factors | 11 | 2018 | 40165 | 0.110 |
Why?
|
Paraffin Embedding | 1 | 2015 | 302 | 0.110 |
Why?
|
Tissue Fixation | 1 | 2015 | 241 | 0.110 |
Why?
|
Osteopontin | 1 | 2015 | 302 | 0.110 |
Why?
|
Formaldehyde | 1 | 2015 | 358 | 0.110 |
Why?
|
Cyclin D1 | 1 | 2015 | 451 | 0.110 |
Why?
|
Gene Expression Profiling | 4 | 2017 | 9411 | 0.110 |
Why?
|
Depression | 2 | 2024 | 8044 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2016 | 9276 | 0.110 |
Why?
|
Anus Neoplasms | 1 | 2016 | 329 | 0.110 |
Why?
|
Socioeconomic Factors | 6 | 2017 | 7806 | 0.100 |
Why?
|
Follow-Up Studies | 15 | 2019 | 39261 | 0.100 |
Why?
|
Telephone | 1 | 2016 | 624 | 0.100 |
Why?
|
Health Status Disparities | 2 | 2014 | 1830 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 895 | 0.100 |
Why?
|
Rectum | 2 | 2014 | 895 | 0.100 |
Why?
|
Medically Uninsured | 2 | 2016 | 843 | 0.100 |
Why?
|
Superoxide Dismutase | 1 | 2015 | 594 | 0.100 |
Why?
|
Nephrectomy | 1 | 2018 | 1016 | 0.100 |
Why?
|
Seminoma | 1 | 2013 | 134 | 0.100 |
Why?
|
Urology | 1 | 2017 | 423 | 0.100 |
Why?
|
Organs at Risk | 1 | 2014 | 358 | 0.100 |
Why?
|
Stromal Cells | 1 | 2017 | 1326 | 0.100 |
Why?
|
Prospective Studies | 8 | 2024 | 54303 | 0.100 |
Why?
|
Survival Rate | 7 | 2016 | 12808 | 0.100 |
Why?
|
Income | 3 | 2014 | 1875 | 0.100 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 412 | 0.090 |
Why?
|
Community Health Services | 1 | 2016 | 654 | 0.090 |
Why?
|
Survival Analysis | 6 | 2018 | 10182 | 0.090 |
Why?
|
Endoribonucleases | 1 | 2013 | 229 | 0.090 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 549 | 0.090 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 380 | 0.090 |
Why?
|
Delphi Technique | 1 | 2014 | 829 | 0.090 |
Why?
|
User-Computer Interface | 1 | 2017 | 1403 | 0.090 |
Why?
|
Treatment Refusal | 1 | 2014 | 430 | 0.090 |
Why?
|
Cohort Studies | 11 | 2020 | 41335 | 0.090 |
Why?
|
Geriatric Assessment | 2 | 2017 | 1405 | 0.090 |
Why?
|
Predictive Value of Tests | 6 | 2018 | 15289 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3959 | 0.090 |
Why?
|
beta Carotene | 1 | 2011 | 524 | 0.090 |
Why?
|
Disease Progression | 6 | 2017 | 13502 | 0.090 |
Why?
|
Medical Informatics | 1 | 2017 | 732 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2557 | 0.090 |
Why?
|
Gene Fusion | 1 | 2012 | 354 | 0.080 |
Why?
|
Retrospective Studies | 17 | 2024 | 80372 | 0.080 |
Why?
|
Enzyme Activation | 1 | 2015 | 3602 | 0.080 |
Why?
|
Edema | 1 | 2013 | 769 | 0.080 |
Why?
|
Sexual Behavior | 1 | 2019 | 2086 | 0.080 |
Why?
|
Consensus | 2 | 2019 | 3113 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2020 | 2781 | 0.080 |
Why?
|
Multivariate Analysis | 6 | 2019 | 12159 | 0.080 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1392 | 0.080 |
Why?
|
Antidepressive Agents | 1 | 2021 | 2890 | 0.080 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2014 | 1153 | 0.080 |
Why?
|
Hyperpigmentation | 1 | 2009 | 117 | 0.080 |
Why?
|
Adult | 20 | 2024 | 219994 | 0.070 |
Why?
|
Cause of Death | 6 | 2018 | 3725 | 0.070 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2009 | 881 | 0.070 |
Why?
|
Health Surveys | 1 | 2017 | 4063 | 0.070 |
Why?
|
Serine Endopeptidases | 1 | 2012 | 1021 | 0.070 |
Why?
|
Genetic Association Studies | 2 | 2015 | 2717 | 0.070 |
Why?
|
Cognition | 1 | 2024 | 6957 | 0.070 |
Why?
|
Propensity Score | 3 | 2021 | 1928 | 0.070 |
Why?
|
Radiotherapy Dosage | 3 | 2023 | 2897 | 0.070 |
Why?
|
Age Factors | 7 | 2018 | 18416 | 0.070 |
Why?
|
Myocardial Infarction | 3 | 2013 | 11891 | 0.070 |
Why?
|
Odds Ratio | 5 | 2017 | 9716 | 0.070 |
Why?
|
Insurance Coverage | 2 | 2014 | 1939 | 0.060 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2013 | 1596 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5889 | 0.060 |
Why?
|
Epithelial Cells | 1 | 2017 | 3663 | 0.060 |
Why?
|
Alopecia | 1 | 2009 | 414 | 0.060 |
Why?
|
Cost of Illness | 1 | 2015 | 1940 | 0.060 |
Why?
|
Vitamins | 1 | 2013 | 1634 | 0.060 |
Why?
|
Farnesyltranstransferase | 1 | 2004 | 71 | 0.060 |
Why?
|
Regression Analysis | 4 | 2016 | 6360 | 0.060 |
Why?
|
Incidence | 7 | 2015 | 21392 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3164 | 0.060 |
Why?
|
Weight Gain | 1 | 2014 | 2347 | 0.060 |
Why?
|
Urogenital System | 1 | 2023 | 88 | 0.060 |
Why?
|
Antioxidants | 1 | 2011 | 1667 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1796 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7593 | 0.060 |
Why?
|
Software | 1 | 2017 | 4419 | 0.050 |
Why?
|
Risk | 4 | 2019 | 9631 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3486 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5508 | 0.050 |
Why?
|
Overweight | 1 | 2014 | 2421 | 0.050 |
Why?
|
Health Care Costs | 1 | 2016 | 3258 | 0.050 |
Why?
|
Trans-Activators | 1 | 2012 | 2860 | 0.050 |
Why?
|
Radiation Tolerance | 2 | 2016 | 480 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 6498 | 0.050 |
Why?
|
Insurance, Health | 1 | 2014 | 2501 | 0.050 |
Why?
|
Sensation Disorders | 1 | 2022 | 160 | 0.050 |
Why?
|
Aspirin | 1 | 2013 | 3364 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 4024 | 0.050 |
Why?
|
Coronary Artery Bypass | 1 | 2010 | 2272 | 0.050 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1630 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5397 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2014 | 4938 | 0.050 |
Why?
|
Fiducial Markers | 1 | 2021 | 132 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11712 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2015 | 12766 | 0.040 |
Why?
|
Coronary Disease | 1 | 2014 | 5990 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2017 | 4775 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2015 | 2932 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4591 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2004 | 2234 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36290 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3836 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2514 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3334 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4878 | 0.040 |
Why?
|
Pharmacogenetics | 1 | 2022 | 680 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2017 | 3775 | 0.040 |
Why?
|
Speech | 1 | 2022 | 550 | 0.040 |
Why?
|
Obesity | 2 | 2024 | 12922 | 0.040 |
Why?
|
Organ Size | 2 | 2013 | 2254 | 0.030 |
Why?
|
Heart Failure | 2 | 2011 | 11847 | 0.030 |
Why?
|
Educational Status | 2 | 2014 | 2515 | 0.030 |
Why?
|
Marriage | 1 | 2018 | 350 | 0.030 |
Why?
|
Cryotherapy | 1 | 2017 | 161 | 0.030 |
Why?
|
Stents | 2 | 2023 | 3314 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 296 | 0.030 |
Why?
|
Data Display | 1 | 2016 | 174 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2017 | 5201 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2419 | 0.030 |
Why?
|
Disabled Persons | 1 | 2024 | 1223 | 0.030 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2014 | 30 | 0.030 |
Why?
|
Goserelin | 1 | 2014 | 127 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1660 | 0.030 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 464 | 0.030 |
Why?
|
Minority Health | 1 | 2014 | 81 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 2015 | 450 | 0.030 |
Why?
|
Survival | 1 | 2013 | 161 | 0.030 |
Why?
|
Community Health Centers | 1 | 2017 | 453 | 0.030 |
Why?
|
Leuprolide | 1 | 2014 | 315 | 0.030 |
Why?
|
Epithelium | 1 | 2017 | 1605 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2021 | 2512 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 551 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2017 | 805 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10827 | 0.020 |
Why?
|
Signal Transduction | 1 | 2015 | 23376 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2014 | 15697 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1673 | 0.020 |
Why?
|
Demography | 1 | 2016 | 1650 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1636 | 0.020 |
Why?
|
Urethra | 1 | 2013 | 406 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 861 | 0.020 |
Why?
|
Neoadjuvant Therapy | 2 | 2013 | 2821 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2015 | 1343 | 0.020 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2013 | 237 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2021 | 2093 | 0.020 |
Why?
|
Waist Circumference | 1 | 2013 | 926 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2919 | 0.020 |
Why?
|
Iodine Radioisotopes | 1 | 2013 | 1032 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16546 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2017 | 8515 | 0.020 |
Why?
|
Young Adult | 4 | 2021 | 58741 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3711 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1575 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1765 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4925 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2295 | 0.020 |
Why?
|
Female | 9 | 2016 | 391270 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 3529 | 0.020 |
Why?
|
Lymphoma, Follicular | 1 | 2013 | 453 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7509 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1885 | 0.020 |
Why?
|
Radiometry | 1 | 2013 | 813 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2916 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2004 | 16939 | 0.020 |
Why?
|
Angioplasty | 1 | 2010 | 361 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 10344 | 0.020 |
Why?
|
History, 20th Century | 1 | 2015 | 2773 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 2943 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3618 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2012 | 1122 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3527 | 0.020 |
Why?
|
Bone and Bones | 1 | 2017 | 2560 | 0.020 |
Why?
|
Physical Examination | 1 | 2013 | 1244 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6544 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4902 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2648 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 1841 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2014 | 1399 | 0.020 |
Why?
|
Body Mass Index | 2 | 2014 | 12914 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17790 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5877 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2014 | 6238 | 0.020 |
Why?
|
Qualitative Research | 1 | 2016 | 2963 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2015 | 2283 | 0.020 |
Why?
|
Up-Regulation | 1 | 2013 | 4122 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 15789 | 0.010 |
Why?
|
Boston | 1 | 2017 | 9280 | 0.010 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2014 | 1200 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 29932 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2145 | 0.010 |
Why?
|
Biopsy | 1 | 2015 | 6771 | 0.010 |
Why?
|
Genome, Human | 1 | 2016 | 4417 | 0.010 |
Why?
|
Body Weight | 1 | 2014 | 4611 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3215 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12626 | 0.010 |
Why?
|
Poverty | 1 | 2014 | 2695 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8803 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6965 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5253 | 0.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2013 | 1628 | 0.010 |
Why?
|
Health Policy | 1 | 2013 | 2677 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3839 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 13981 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10547 | 0.010 |
Why?
|
Registries | 1 | 2016 | 8469 | 0.010 |
Why?
|
Animals | 1 | 2011 | 167963 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 87810 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10551 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 12960 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2011 | 12427 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2013 | 7475 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10756 | 0.010 |
Why?
|
Child | 1 | 2021 | 79806 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15757 | 0.000 |
Why?
|